Cargando…
Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease
Background: Diabetes is a major risk factor for developing cardiovascular disease. Patients with both diabetes and cardiovascular disease have even higher mortality. The convergence of cardiology and diabetology therapy is an important step in treating patients and advancing research. Results: Major...
Autores principales: | Chan, Jonathan C.H., Chan, Michael C.Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893147/ https://www.ncbi.nlm.nih.gov/pubmed/35546744 http://dx.doi.org/10.2174/1573403X18666220511114443 |
Ejemplares similares
-
Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go
por: Gajjela, Harini, et al.
Publicado: (2021) -
Dosing Challenges and Benefits of Vericiguat in a Patient With Decompensated Heart Failure: A Case Report
por: Speranza-Sánchez, Mario, et al.
Publicado: (2023) -
The Intravenous Drug User with a Big Heart
por: Bhagat, Abhishek, et al.
Publicado: (2018) -
Assessment of the Safety, Efficacy, and Benefit of Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Heart Failure With Reduced Ejection Fraction (HFrEF) at High Risk for Cardiovascular Events
por: Towiargi, Ruba, et al.
Publicado: (2022) -
Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review
por: Georgiou, Petros, et al.
Publicado: (2021)